BioCentury | May 1, 2020
Distillery Therapeutics

The lipids LXA4 and RvD1 as treatment for E. coli pneumonia

DISEASE CATEGORY: Infectious disease INDICATION: Escherichia; pneumonia The lipids LXA4 and RvD1, ligands of the membrane receptor FPRL1, could treat E. coli pneumonia by promoting antibacterial functions in neutrophils. The release of neutrophil elastase, induced...
BC Innovations | Jul 26, 2019
Translation in Brief

GI infection as Parkinson’s trigger

A Canadian team has shown how bacterial GI infections can trigger Parkinson's disease in genetically susceptible individuals. The findings add to mounting evidence implicating the gut microbiome in CNS disorders including autism, Alzheimer's disease and...
BC Innovations | Jul 11, 2019
Translation in Brief

PARP inhibitors plus senolytics: a double hit on cancer

A new approach to synthetic lethality aims to overcome resistance to PARP inhibitors by pairing them with senolytic agents, marking one of the first moves beyond DNA damage repair combinations. PARP inhibitors hinder DNA damage...
BioCentury | Dec 14, 2018
Emerging Company Profile

ExCellThera’s safer allogeneic transplants

ExCellThera Inc. is expanding cord blood into allogeneic stem cell transplants for cancer that have lower treatment-related mortality rates and GvHD incidence than competing technologies. Hematopoietic stem cell transplants (HSCTs) of unexpanded cord blood have...
BC Extra | Dec 5, 2018
Tools & Techniques

Proteogenomic screen identifies non-mutated tumor-specific antigens

A University of Montreal team has developed a proteogenomic screen that identifies mutated and non-mutated tumor-specific TCR antigens, including those arising from normally non-coding nucleotide sequences. The technique could help develop T cell immunotherapies targeting...
BC Innovations | Nov 13, 2018
Distillery Therapeutics

Hepatic

INDICATION: Liver fibrosis Patient sample and mouse studies suggest antagonizing AHR or RORγT could help treat liver fibrosis. In liver tissue samples from hepatitis patients, levels of IL-17A and IL-22, which are positively regulated by...
BC Innovations | Dec 8, 2017
Translation in Brief

ADAM and Ephrin

An October study in Nature Medicine from researchers at Harvard Medical School and the University of Montreal has shown inhibiting the cell surface protease ADAM10 could treat a form of idiopathic pulmonary fibrosis mediated by...
BC Innovations | Oct 31, 2017
Distillery Therapeutics

Cancer

INDICATION: Lymphoma; melanoma Mouse studies suggest inhibiting GSK3 could help treat lymphoma and melanoma. In a mouse model of lymphoma, a GSK3 inhibitor tool compound decreased tumor growth and increased survival compared with no treatment,...
BC Innovations | Oct 24, 2017
Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Mouse studies suggest inhibiting ADAM10 could help treat idiopathic pulmonary fibrosis (IPF). In a mouse model of IPF, an ADAM10 inhibitor tool compound decreased fibrosis in the lung and increased survival compared...
BC Innovations | May 8, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts SMARCD2 -knockout mouse and zebrafish models could be used to screen therapies for neutrophil-specific granule deficiency, a congenital immunodeficiency. Whole-exome sequencing in four patients identified splice site and frameshift mutations in...
Items per page:
1 - 10 of 86
BioCentury | May 1, 2020
Distillery Therapeutics

The lipids LXA4 and RvD1 as treatment for E. coli pneumonia

DISEASE CATEGORY: Infectious disease INDICATION: Escherichia; pneumonia The lipids LXA4 and RvD1, ligands of the membrane receptor FPRL1, could treat E. coli pneumonia by promoting antibacterial functions in neutrophils. The release of neutrophil elastase, induced...
BC Innovations | Jul 26, 2019
Translation in Brief

GI infection as Parkinson’s trigger

A Canadian team has shown how bacterial GI infections can trigger Parkinson's disease in genetically susceptible individuals. The findings add to mounting evidence implicating the gut microbiome in CNS disorders including autism, Alzheimer's disease and...
BC Innovations | Jul 11, 2019
Translation in Brief

PARP inhibitors plus senolytics: a double hit on cancer

A new approach to synthetic lethality aims to overcome resistance to PARP inhibitors by pairing them with senolytic agents, marking one of the first moves beyond DNA damage repair combinations. PARP inhibitors hinder DNA damage...
BioCentury | Dec 14, 2018
Emerging Company Profile

ExCellThera’s safer allogeneic transplants

ExCellThera Inc. is expanding cord blood into allogeneic stem cell transplants for cancer that have lower treatment-related mortality rates and GvHD incidence than competing technologies. Hematopoietic stem cell transplants (HSCTs) of unexpanded cord blood have...
BC Extra | Dec 5, 2018
Tools & Techniques

Proteogenomic screen identifies non-mutated tumor-specific antigens

A University of Montreal team has developed a proteogenomic screen that identifies mutated and non-mutated tumor-specific TCR antigens, including those arising from normally non-coding nucleotide sequences. The technique could help develop T cell immunotherapies targeting...
BC Innovations | Nov 13, 2018
Distillery Therapeutics

Hepatic

INDICATION: Liver fibrosis Patient sample and mouse studies suggest antagonizing AHR or RORγT could help treat liver fibrosis. In liver tissue samples from hepatitis patients, levels of IL-17A and IL-22, which are positively regulated by...
BC Innovations | Dec 8, 2017
Translation in Brief

ADAM and Ephrin

An October study in Nature Medicine from researchers at Harvard Medical School and the University of Montreal has shown inhibiting the cell surface protease ADAM10 could treat a form of idiopathic pulmonary fibrosis mediated by...
BC Innovations | Oct 31, 2017
Distillery Therapeutics

Cancer

INDICATION: Lymphoma; melanoma Mouse studies suggest inhibiting GSK3 could help treat lymphoma and melanoma. In a mouse model of lymphoma, a GSK3 inhibitor tool compound decreased tumor growth and increased survival compared with no treatment,...
BC Innovations | Oct 24, 2017
Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Mouse studies suggest inhibiting ADAM10 could help treat idiopathic pulmonary fibrosis (IPF). In a mouse model of IPF, an ADAM10 inhibitor tool compound decreased fibrosis in the lung and increased survival compared...
BC Innovations | May 8, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts SMARCD2 -knockout mouse and zebrafish models could be used to screen therapies for neutrophil-specific granule deficiency, a congenital immunodeficiency. Whole-exome sequencing in four patients identified splice site and frameshift mutations in...
Items per page:
1 - 10 of 86